Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Century Therapeutics (IPSC) EBITDA (2022 - 2025)

Century Therapeutics (IPSC) has disclosed EBITDA for 4 consecutive years, with -$34.4 million as the latest value for Q3 2025.

  • On a quarterly basis, EBITDA fell 14.2% to -$34.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$27.2 million, a 78.75% increase, with the full-year FY2024 number at -$126.4 million, up 5.78% from a year prior.
  • EBITDA was -$34.4 million for Q3 2025 at Century Therapeutics, down from -$32.8 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $76.5 million in Q1 2025 to a low of -$39.5 million in Q1 2022.
  • A 4-year average of -$25.6 million and a median of -$31.8 million in 2022 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: decreased 24.38% in 2023, then soared 369.41% in 2025.
  • Century Therapeutics' EBITDA stood at -$30.5 million in 2022, then fell by 24.38% to -$38.0 million in 2023, then increased by 3.89% to -$36.5 million in 2024, then grew by 5.66% to -$34.4 million in 2025.
  • Per Business Quant, the three most recent readings for IPSC's EBITDA are -$34.4 million (Q3 2025), -$32.8 million (Q2 2025), and $76.5 million (Q1 2025).